Ken Hess is Director, Business Development at Neurvati Neurosciences and GRIN Therapeutics. He began his career as a consultant at Defined Health (subsequently Cello Health and Lumanity), supporting biopharmaceutical and investment firms across multiple therapeutic areas and project types including opportunity assessments, indication prioritizations, gap analyses, and S&E. In 2016, he took on roles in business development at Purdue Pharma and Otsuka Pharma, where he led the scientific and commercial evaluations of assets at all development stages. Most recently, Ken held leadership roles in S&E and business development finance at I-Mab Biopharma and Volastra Therapeutics. He earned a BA in economics from Franklin & Marshall College, a PhD in pharmacology from Weill Cornell Graduate School of Medical Sciences, and an MBA from the S.C. Johnson Graduate School of Management at Cornell University.